Drug Profile

Personalised prostate cancer therapy - BriaCell Therapeutics

Alternative Names: Bria-Pros; Bria-Pros+

Latest Information Update: 14 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BriaCell Therapeutics Corp
Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Cell replacements; Immunologic cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Prostate cancer

Most Recent Events

08 Nov 2024 Pharmacodynamics data from preclinical studies in Prostate cancer released by BriaCell
10 Sep 2024 BriaCell intends to file an IND application in Prostate cancer
10 Sep 2024 BriaCell receives positive feedback from its pre-IND meeting with the US FDA for its personalised prostate cancer therapy

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com